

Greetings!

### ***The Quarterly Data Matters Training Newsletter is Back!***

The Data Matters Training Newsletter will be sent out quarterly in January, April, July and October.

### ***Multiple Myeloma and Lymphoma Questions***

As a reminder, any center emailing their CRC about a multiple myeloma question must fill out the disease tracker in [Appendix G](#) of the Data Manual. By filling out the tracker in advance, it allows the CRC to see the "big picture" and respond in a timely manner.

### ***Specific Instructions for the Reporting of Flow Cytometry for Multiple Myeloma and Lymphoma have been REMOVED from the Forms Instruction Manual***

Centers can now report **negative** Flow Cytometry Assessments for Multiple Myeloma and Lymphoma. Flow cytometry has improved over the years leading to increased sensitivity for reporting negative disease status.

- **"yes"** if flow cytometry was performed in the reporting period
- **"no"** if flow cytometry was not performed in the reporting period
- **"not applicable"** if flow was never performed since diagnosis or has never shown evidence of disease

Questions, feedback, or requests may be submitted directly on the manual website using the Feedback Feature at the bottom of each page. For more information on how to submit feedback, click [here](#).

### ***The following forms are being revised / developed:***

<b>Form</b>	<b>Anticipated Release Date</b>
Cellular Therapy Product (4003)	Winter Release 2019
Hodgkin & Non-Hodgkin Lymphoma Pre-HCT (2018)	Winter Release 2019
Recipient Death Data (2900)	Winter Release 2019
Indication for CRID Assignment (2814)	Spring Release 2019
BMT CTN 1702 Supplemental Form (2532) *	Spring Release 2019
SRG Study Contact Form *	Spring Release 2019
Tocilizumab Supplemental Form *	Spring Release 2019
CRID Assignment Form (2804)	Summer Release 2019
Pre-Transplant Essential Data (2400)	Summer Release 2019
Pre-TED Disease Classification (2402)	Summer Release 2019
Recipient Baseline Data (2000)	Summer Release 2019
Infectious Disease Markers (2004)	Summer Release 2019
Confirmation of HLA Typing (2005)	Summer Release 2019
HCT Infusion (2006)	Summer Release 2019

Post-Transplant Essential Data (2450)	Summer Release 2019
Plasma Cell Disorders/Multiple Myeloma (2016/2116) **	Fall Release 2019

\*New Form

\*\*Accepting volunteers to help with Form Revision **NOW**

To volunteer for Form Revision review teams, get more information about the upcoming release, or comment on current form revisions, please contact: [cibmtrformfeedback@nmdp.org](mailto:cibmtrformfeedback@nmdp.org)

## Manual Helpful Hints: Red and Blue Callout Boxes

The Forms Instruction Manual contains red and blue callout boxes that contain important reporting instructions or instructions on how to report specific scenarios. When reviewing the manual, please also review these boxes to prevent any reporting errors. See an example of these callout boxes below from the preparative regimen section on the pre-TED form (2400).



### Preparative Regimen – Drugs

The following questions report the **prescribed** drug therapy that was part of the preparative regimen. Do not report the dose that was actually given. If the recipient has comprehensive report forms due, the actual dose given will be reported on the Recipient Baseline Form (Form 2000). **Do not include drugs that are intended to offset the side effects of the chemotherapy** (e.g., corticosteroids for nausea, MESNA for hemorrhagic cystitis, etc.).



### Drugs After Transplant

Occasionally, protocols list drugs that may be given before and after transplant. If the drugs are planned to be given before and after transplant, only the doses given before transplant should be quantified in the preparative regimen section. The doses given after transplant should be reported in the **Post-HCT Disease Therapy Planned as of Day 0** or **GVHD Prophylaxis** section. For example, if bortezomib or rituximab is planned to be given on Days -2, +1, +4, and +7, report the Day -2 dose in the preparative regimen section, and the post-transplant doses as planned post-HCT therapy.

### Quick Links

[CIBMTR Online Training webpage](#) - to read course descriptions and access eLearning modules  
[CIBMTRRecipientForms@nmdp.org](mailto:CIBMTRRecipientForms@nmdp.org) - to submit recipient forms and communications to CRCs  
[Look Up Your CRC](#) - to discover who your assigned CRC is by entering your name and center  
[Past Newsletters and eBlasts](#) - to refresh your memory on news we've sent  
[cibmtrformfeedback@nmdp.org](mailto:cibmtrformfeedback@nmdp.org) - send comments about forms or volunteering for forms revision

### CIBMTR on Facebook and Twitter

Like us on Facebook and follow us on Twitter to stay up-to-date with important news and events. We promote our publications, share important content from other organizations, and advertise our key meetings and events. Join us today!

[facebook.com/theCIBMTR](https://www.facebook.com/theCIBMTR)

[@CIBMTR](https://twitter.com/CIBMTR)



CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a research collaboration between the National Marrow Donor Program®/Be The Match® and Medical College of Wisconsin.

